KEGG   DRUG: Etranacogene dezaparvovec
Entry
D12500                      Drug                                   
Name
Etranacogene dezaparvovec (USAN/INN);
Etranacogene dezaparvovec-drlb;
Hemgenix (TN)
Product
HEMGENIX (CSL Behring)
Class
Blood modifier agent
 DG02016  Hemostatics
  DG02014  Blood coagulation accelerant
   DG02013  Blood coagulation factor
Remark
ATC code: B02BD16
Product: D12500<US>
Efficacy
Bleeding suppressant
  Disease
Hemophilia B, congenital Factor IX deficiency [DS:H00219]
  Type
Gene therapy product
Comment
Adeno-associated virus serotype 5 (AAV5) based gene therapy designed to deliver a copy of a gene encoding the Padua variant of human coagulation Factor IX
Target
F9 [HSA:2158] [KO:K01321]
  Pathway
hsa04610  Complement and coagulation cascades
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 B BLOOD AND BLOOD FORMING ORGANS
  B02 ANTIHEMORRHAGICS
   B02B VITAMIN K AND OTHER HEMOSTATICS
    B02BD Blood coagulation factors
     B02BD16 Etranacogene dezaparvovec
      D12500  Etranacogene dezaparvovec (USAN/INN) <US>
Drug groups [BR:br08330]
 Blood modifier agent
  DG02016  Hemostatics
   DG02014  Blood coagulation accelerant
    DG02013  Blood coagulation factor
     D12500  Etranacogene dezaparvovec
Target-based classification of drugs [BR:br08310]
 Enzymes
  Hydrolases (EC3)
   Serine peptidases
    F9
     D12500  Etranacogene dezaparvovec (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 Cellular and gene therapy products
  D12500
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12500
 Cellular and gene therapy products
  D12500
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12500
Other DBs
CAS: 2156583-26-3
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system